{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:46Z","timestamp":1784408866298,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.7759\/cureus.107090","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:39:31Z","timestamp":1776260371000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Treatment of Refractory Palmoplantar Pustulosis With Bimekizumab in a Patient With Multiple Sclerosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Osman","family":"Mahboob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Acosta-Pe\u00f1aloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittani","family":"Kongala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Amawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.5051","article-title":"Treatment of severe palmoplantar pustular psoriasis With bimekizumab","volume":"160","author":"Passeron T","year":"2024","unstructured":"Passeron T, Perrot JL, Jullien D, et al.. Treatment of severe palmoplantar pustular psoriasis With bimekizumab. JAMA Dermatol. 2024, 160:199-203. 10.1001\/jamadermatol.2023.5051","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7612","article-title":"Palmoplantar pustulosis: therapy update","volume":"23","author":"Devjani S","year":"2024","unstructured":"Devjani S, Smith B, Javadi SS, Engel PV, Han G, Wu JJ. Palmoplantar pustulosis: therapy update. J Drugs Dermatol. 2024, 23:626-31. 10.36849\/JDD.7612","journal-title":"J Drugs Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams R","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al.. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020, 11:1894. 10.3389\/fimmu.2020.01894","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo H","year":"2021","unstructured":"Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021, 12:6. 10.1177\/20406223211037846","journal-title":"Ther Adv Chronic Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-016-0624-7","article-title":"Unintended immunological consequences of biologic therapy","volume":"16","author":"Henrickson SE","year":"2016","unstructured":"Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016, 16:46. 10.1007\/s11882-016-0624-7","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10233.x","article-title":"Management of palmoplantar pustulosis: do we need to change?","volume":"164","author":"Mrowietz U","year":"2011","unstructured":"Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change?. Br J Dermatol. 2011, 164:942-6. 10.1111\/j.1365-2133.2011.10233.x","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.03.035","article-title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease","volume":"152","author":"Cole S","year":"2023","unstructured":"Cole S, Manghera A, Burns L, et al.. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023, 152:783-98. 10.1016\/j.jaci.2023.03.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger JG","year":"2012","unstructured":"Krueger JG, Fretzin S, Su\u00e1rez-Fari\u00f1as M, et al.. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012, 130:145-54.e9. 10.1016\/j.jaci.2012.04.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis E","year":"2014","unstructured":"Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014, 13:54-8. 10.1016\/j.autrev.2013.09.002","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1 E","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A, et al.. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016, 263:1287-95. 10.1007\/s00415-016-8128-x","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02113.x","article-title":"Palmoplantar pustulosis: a clinical and immunohistological study","volume":"138","author":"Eriksson MO","year":"1998","unstructured":"Eriksson MO, Hagforsen E, Lundin IP, Micha\u00eblsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998, 138:390-8. 10.1046\/j.1365-2133.1998.02113.x","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462734-successful-treatment-of-refractory-palmoplantar-pustulosis-with-bimekizumab-in-a-patient-with-multiple-sclerosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:39:32Z","timestamp":1776260372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462734-successful-treatment-of-refractory-palmoplantar-pustulosis-with-bimekizumab-in-a-patient-with-multiple-sclerosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.107090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}